Dexpramipexole attenuates myocardial ischemia/reperfusion injury through upregulation of mitophagy

Area of Science:

• Cardiovascular Biology
• Mitochondrial Medicine
• Pharmacology

Background:

• Reperfusion injury damages the heart muscle after restoring blood flow to ischemic areas.
• Understanding protective mechanisms against myocardial ischemia/reperfusion injury is crucial for cardiovascular health.
• Mitochondrial dysfunction plays a key role in the pathogenesis of ischemia/reperfusion injury.

Purpose of the Study:

• To evaluate the protective effects of dexpramipexole (DPX) against myocardial injury induced by ischemia/reperfusion (I/R) in vivo and hypoxia/reoxygenation (H/R) in vitro.
• To investigate the underlying functional mechanisms of DPX's cardioprotective action.
• To explore the role of mitophagy, PINK1, and Parkin in DPX-mediated protection.

Main Methods:

• In vivo assessment of DPX effects on myocardial infarct size and tissue damage following I/R.
• In vitro evaluation of DPX's impact on H/R-induced cellular damage and mitochondrial function.
• Analysis of mitophagy, PINK1, and Parkin expression and activity, including siRNA-mediated knockdown studies.

Main Results:

• DPX treatment significantly reduced myocardial infarct size and tissue damage in I/R models.
• DPX protected cells against H/R-induced mitochondrial dysfunction and cellular damage in vitro.
• DPX enhanced mitophagy, accompanied by increased expression of PINK1 and Parkin, which was essential for its protective effects.

Conclusions:

• Dexprapexole (DPX) demonstrates significant cardioprotective effects against ischemia/reperfusion injury.
• DPX-mediated protection is associated with the enhancement of mitophagy via the PINK1/Parkin pathway.
• Targeting mitophagy represents a potential therapeutic strategy for mitigating reperfusion injury.